Tag Archive for: Podcast

Posts

Podcast: NICE Guidance. Pelvic floor dysfunction: prevention and non-surgical management

Part of the BURST/BJUI podcast series

Miss Sanya Caratella is a CT2 in urology in the East Midlands.

British Urology Researchers in Surgical Training (BURST) is a research collaborative primarily of urological researchers in the UK. Their aim is to produce high impact multi-centre audit and research which can improve patient care.

Podcast: NICE Guidance. Urinary tract infection in under 16s: diagnosis and management

Part of the BURST/BJUI podcast series

Mr Harmony Uwadiae is an CT2 in Urology in the East Midlands Deanery and also a member of BURST.

British Urology Researchers in Surgical Training (BURST) is a research collaborative primarily of urological researchers in the UK. Their aim is to produce high impact multi-centre audit and research which can improve patient care.

Podcast from BJUI Knowledge: bladder function after in utero myelomeningocele repair

 


Paediatric urologist Antonio Macedo, author of e-learning module Postnatal bladder function after in utero repair of myelomeningocele: a literature review talks to Stephen Griffin.

BJUI Knowledge: The CPD portal for urologists

Comprehensive, trustworthy and easy to use e-learning platform for trainees, residents, consultants and all specialising in urology.

  • Accredited by the Royal College of Surgeons Edinburgh and the College of Surgeons of Hong Kong.
  • Approved by the Royal Australasian College of Surgeons.

BJUI Knowledge is evidence-based, fully referenced and peer reviewed to ensure academic, scientific and editorial validity.

Podcast from BJUI Knowledge: prostate cancer screening

 

Author Monique Roobol talks to associate editor Greg Shaw about screening for prostate cancer.

BJUI Knowledge: The CPD portal for urologists

Comprehensive, trustworthy and easy to use e-learning platform for trainees, residents, consultants and all specialising in urology.

  • Accredited by the Royal College of Surgeons Edinburgh and the College of Surgeons of Hong Kong.
  • Approved by the Royal Australasian College of Surgeons.

BJUI Knowledge is evidence-based, fully referenced and peer reviewed to ensure academic, scientific and editorial validity.

 

Podcast: The IDENTIFY Study

Part of the BURST/BJUI podcast series

Podcast:  The IDENTIFY Study: The investigation and detection of urological neoplasia in patients referred with suspected urinary tract cancer; a multicentre observational study 

Mr Sinan Khadhouri is a Specialty Registrar in Urology in the East of Scotland and currently doing his PhD at the University of Aberdeen. He is also the co-vice chair of BURST and the lead trainee on IDENTIFY.

Read the full article

Podcast: Early outcomes of single‐port robot‐assisted radical prostatectomy: lessons learned from the learning‐curve experience

Part of the BURST/BJUI podcast series

Arjun Nathan is an ST1 in Urology in North London and NIHR Academic Clinical Fellow with the Royal College of Surgeons. He is also the BURST Treasurer and committee member.
Read the full article

Podcast: Machine learning partial nephrectomy complications

Part of the BURST/BJUI Podcast Series

Arjun Nathan is an ST1 in Urology in North London and NIHR Academic Clinical Fellow with the Royal College of Surgeons. He is also the BURST Treasurer and committee member.

Read the full article

Residents’ Podcast: Efficacy of vibegron, a novel β3‐adrenoreceptor agonist, on severe UUI related to OAB

Part of the BURST/BJUI Podcast Series

Nikita Bhatt is a Specialist Trainee in Urology in the East of England Deanery and a BURST Committee member @BURSTUrology

Efficacy of vibegron, a novel β3‐adrenoreceptor agonist, on severe urgency urinary incontinence related to overactive bladder: post hoc analysis of a randomized, placebo‐controlled, double‐blind, comparative phase 3 study

Masaki Yoshida*, Masayuki Takeda, Momokazu Gotoh, Osamu Yokoyama§, Hidehiro Kakizaki, Satoru Takahashi**, Naoya Masumori††, Shinji Nagai‡‡ and Kazuyoshi Minemura‡‡

*Department of Urology, National Centre for Geriatrics and Gerontology, Obu, Department of Urology, University of Yamanashi, Graduate School of Medical Sciences, Kofu, Japan, Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, §Department of Urology, Faculty of Medical Science, University of Fukui, Fukui, Department of Renal and Urological Surgery, Asahikawa Medical University, Asahikawa, Japan, **Department of Urology, Nihon University School of Medicine, Tokyo, ††Department of Urology, Sapporo Medical University School of Medicine, Sapporo, and ‡‡Kyorin Pharmaceutical Co., Ltd., Tokyo, Japan

Read the full article

Abstract

Objective

To evaluate the efficacy of a novel and selective β3‐adrenoreceptor agonist vibegron on urgency urinary incontinence (UUI) in patients with overactive bladder (OAB). Follow us visaliaweddingstyle for more details .

Patients and Methods

post hoc analysis was performed in patients with UUI (>0 episodes/day) who were assigned to receive vibegron or placebo in a vibegron phase 3 study. Patients were subclassified into mild/moderate (>0 to <3 UUI episodes/day) or severe UUI (≥3 UUI episodes/day) subgroup. Changes from baseline in number of UUI episodes/day, in number of urgency episodes/day, and in voided volume/micturition were compared between the groups. The percentage of patients who became UUI‐free (‘diary‐dry’ rate) and the response rate (percentage of patients with scores 1 [feeling much better] or 2 [feeling better] assessed by the Patient Global Impression scale [PGI]) were evaluated.

Results

Changes in numbers of UUI episodes at week 12 in the vibegron 50 mg, vibegron 100 mg and placebo groups, respectively, were −1.35, −1.47 and −1.08 in all patients, −1.04, −1.13 and −0.89 in the mild/moderate UUI subgroup, and −2.95, −3.28 and −2.10 in the severe UUI subgroup. The changes were significant in the vibegron 50 and 100 mg groups vs placebo regardless of symptom severity. Change in number of urgency episodes/day was significant in the vibegron 100 mg group vs placebo in all patients and in both severity subgroups. In the vibegron 50 mg group, a significant change vs placebo was observed in all patients and in the mild/moderate UUI subgroup. Change in voided volume/micturition was significantly greater in the vibegron 50 and 100 mg groups vs placebo in all patients, as well as in the both severity subgroups. Diary‐dry rates in the vibegron 50 and 100 mg groups were significantly greater vs placebo in all patients and in the mild/moderate UUI subgroup. In the severe UUI subgroup, however, a significant difference was observed only in the vibegron 50 mg group. Response rates assessed by the PGI were significantly higher in the vibegron groups vs placebo in all patients and in the both severity subgroups. Vibegron administration, OAB duration ≤37 months, mean number of micturitions/day at baseline <12.0 and mean number of UUI episodes/day at baseline <3.0 were identified as factors significantly associated with normalization of UUI.

Conclusions

Vibegron, a novel β3‐adrenoreceptor agonist, significantly reduced the number of UUI episodes/day and significantly increased the voided volume/micturition in patients with OAB including those with severe UUI, with the response rate exceeding 50%. These results suggest that vibegron can be an effective therapeutic option for OAB patients with UUI.

More podcasts

Residents’ podcast: the ProtecT trial

Mr Joseph Norris is a Specialty Registrar in Urology in the London Deanery. He is currently undertaking an MRC Doctoral Fellowship at UCL, under the supervision of Professor Mark Emberton. His research interest is prostate cancer that is inconspicuous on mpMRI. Joseph sits on the committee of the BURST Research Collaborative as the Treasurer and BSoT Representative.

The ProtecT trial: analysis of the patient cohort, baseline risk stratification and disease progression

Read the full article

Abstract

Objective

To test the hypothesis that the baseline clinico‐pathological features of the men with localized prostate cancer (PCa) included in the ProtecT (Prostate Testing for Cancer and Treatment) trial who progressed (n = 198) at a 10‐year median follow‐up were different from those of men with stable disease (n = 1409).

Patients and Methods

We stratified the study participants at baseline according to risk of progression using clinical disease stage, pathological grade and PSA level, using Cox proportional hazard models.

Results

The findings showed that 34% of participants (n = 505) had intermediate‐ or high‐risk PCa, and 66% (n = 973) had low‐risk PCa. Of 198 participants who progressed, 101 (51%) had baseline International Society of Urological Pathology Grade Group 1, 59 (30%) Grade Group 2, and 38 (19%) Grade Group 3 PCa, compared with 79%, 17% and 5%, respectively, for 1409 participants without progression (P < 0.001). In participants with progression, 38% and 62% had baseline low‐ and intermediate‐/high‐risk disease, compared with 69% and 31% of participants with stable disease (P < 0.001). Treatment received, age (65–69 vs 50–64 years), PSA level, Grade Group, clinical stage, risk group, number of positive cores, tumour length and perineural invasion were associated with time to progression (P ≤ 0.005). Men progressing after surgery (n = 19) were more likely to have a higher Grade Group and pathological stage at surgery, larger tumours, lymph node involvement and positive margins.

Conclusions

We demonstrate that one‐third of the ProtecT cohort consists of people with intermediate‐/high‐risk disease, and the outcomes data at an average of 10 years’ follow‐up are generalizable beyond men with low‐risk PCa.

More podcasts

BJUI Podcasts are available on iTunes: https://itunes.apple.com/gb/podcast/bju-international/id1309570262

Podcast: Covid-19: the situation in Italy

Dr Riccardo Campi is a resident in Urology and PhD student at the Department of Urology and Renal Transplantation, Careggi University Hospital in Florence, Italy

More podcasts

BJUI Podcasts are available on iTunes: https://itunes.apple.com/gb/podcast/bju-international/id1309570262

© 2022 BJU International. All Rights Reserved.